Last reviewed · How we verify
Xembify
At a glance
| Generic name | Xembify |
|---|---|
| Also known as | Immune Globulin Subcutaneous (Human), 20% (IGSC 20%) |
| Sponsor | Grifols Therapeutics LLC |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |